Key facts
- This page summarizes Patrick Lin's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 12 Oct 2023, 18:01.
Patrick Lin - 12 Oct 2023 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)
- Reporting relationship
- Chief Business - Strategy Off
- Issuer ticker
- PCSA
- Reported as of
- 12 Oct 2023
- Net transaction value
- +$1,600
- SEC form
- 4
- Accepted by SEC
- 12 Oct 2023, 18:01:20 UTC
- Prior SEC filing
- 10 Oct 2023
- Next SEC filing
- 12 Apr 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Patrick Lin by Michael B. Kirwan, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Patrick Lin filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 12 Oct 2023.
Change
- Previous filing in this sequence was filed on 10 Oct 2023.
- Current net transaction value: +$1,600.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCSA
transaction
Common Stock
Award
- Transaction value
- $1,600
- Shares
- +5,000
- Change %
- +1.1%
- Price
- $0.3200
- Shares after
- 469,535
- Date
- 12 Oct 2023
- Ownership
- Direct
* marks a reported price that did not pass the local price check.